Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

Inclusion Criteria: * Age \>= 18 years of age * Surgically resected stage II, III, or IV melanoma with no evidence of disease according to the American Joint Committee on Cancer (AJCC) classification criteria * Eligible for adjuvant CPI treatment per treating physician discretion * Plan to continue care at MD Anderson Cancer Center (MDACC) * Ability to communicate and read in English language Exclusion Criteria: * Previous systemic therapy for melanoma * Previous history of other cancers treated with immunotherapy * Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded * Previous cancer that has been resected two or more years ago are not excluded. * Previous history of inflammatory or autoimmune diseases. This include but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or psoriasis. Patients with autoimmune thyroid disease, vitiligo, and type I diabetes mellitus are not excluded. * Other concurrent malignancies that require active therapy * Participants \< 18 years of age and pregnant women are not eligible to participate in this study